Pharvaris says Phase 3 CHAPTER-3 trial shows 83% cut in HAE attack rate for deucrictibant XR vs placebo

PUBT · 2d ago
Pharvaris says Phase 3 CHAPTER-3 trial shows 83% cut in HAE attack rate for deucrictibant XR vs placebo
  • Pharvaris reported positive topline results from its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR to prevent hereditary angioedema attacks.
  • The trial met its main goal, showing a clear reduction in attack frequency versus placebo across all hereditary angioedema types studied.
  • Safety looked consistent with prior data, supporting a potential oral alternative to injectable prevention options.
  • Additional efficacy and safety details will be presented at upcoming medical congresses.
  • Regulatory submissions for the preventive use are planned to start in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080650PRIMZONEFULLFEED9822705) on September 08, 2026, and is solely responsible for the information contained therein.